Integrated DNA Technologi?es Enhances its qPCR Probe Portfolio
Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, has further expanded its portfolio of PrimeTime® qPCR products with the launch of two new probes. The PrimeTime Eco Probe and PrimeTime Mini LNA Probe complete the existing offering, providing new options for customers performing gene expression and genotyping experiments.
Developed to support customers looking for a cost-effective option at the mid-scale range, the Eco Probe is delivered at a normalised yield of 2.5 nmoles, sufficient for approximately 500 reactions, bridging the space between the existing PrimeTime Mini qPCR Probe (0.5 nmole normalized yield, 100 reactions) and the 100 nmole synthesis scale (minimum guaranteed yield of 10 nmoles). If ordered with the option of an internal ZEN quencher, the double-quenched PrimeTime Eco Probe will generate less background noise, while increasing end point signal, to significantly boost qPCR sensitivity and precision when compared to traditional single-quenched probes. The Eco Probe is available with a FAM/ZEN/IA Black FQ dye/quencher combination.
When genotyping via PCR, it is often useful to be able to perform a few reactions using a small subset of probes, in order to test and consequently optimise LNA probe design. The new PrimeTime Mini LNA Probes enable customers to do as few as 100 reactions, allowing preliminary experiments to be performed at a low initial cost.
Guidelines for LNA probe design are available online, under the Overview tab to aid users in their initial design. IDT can also provide full design support, if required — design fees may apply. The Mini LNA Probes join the existing 250 nmole PrimeTime LNA Probes, which provide 8000 reactions and are ideal for large-scale screening.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance